PT-141 (Bremelanotide)
1–2 mg · As needed (max 1×/72h)
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 2 cited sources
Evidence
- Human Studies
- 15
- Animal Studies
- 20
- Clinical Status
- FDA Approved
- Confidence
- Moderate
- Long-Term Safety
- Established for the approved indication and population; male off-label use has less formal long-term data
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A melanocortin receptor agonist (MC3R/MC4R) that acts centrally on the nervous system rather than on vascular pathways the way PDE5 inhibitors (e.g. sildenafil) do. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; off-label male use is common but has less formal trial data specific to men.
Common Protocols
- 1–2 mg subcutaneous, roughly 45 minutes before activity, no more than about once every 72 hours per approved labeling
Side Effects
- Nausea (common, often dose-limiting)
- Flushing, headache
- Transient increase in blood pressure
Interactions
- Caution combining with other medications that affect blood pressure
Practical Details
- Cost
- $$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Kingsberg SA et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. PMID 31599840.
- Simon JA et al. (2019). Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. PMID 31599847.
Search the Research
PT-141 (Bremelanotide) FAQ
What is the typical PT-141 (Bremelanotide) dosage?
Commonly reported protocols: 1–2 mg subcutaneous, roughly 45 minutes before activity, no more than about once every 72 hours per approved labeling. Our reference entry uses 1–2 mg, As needed (max 1×/72h). These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of PT-141 (Bremelanotide)?
Reported side effects include: Nausea (common, often dose-limiting); Flushing, headache; Transient increase in blood pressure.
Is PT-141 (Bremelanotide) FDA approved?
PT-141 (Bremelanotide) is FDA-approved for specific medical indications (described in the summary above). Use for anything else is off-label and should be supervised by a prescriber.
How much research is there on PT-141 (Bremelanotide)?
Our evidence profile counts roughly 15 human and 20 animal studies, with moderate overall confidence. Long-term safety: Established for the approved indication and population; male off-label use has less formal long-term data.
Does PT-141 (Bremelanotide) interact with other drugs or supplements?
Caution combining with other medications that affect blood pressure.
How do I reconstitute PT-141 (Bremelanotide)?
A common setup is a 10 mg vial mixed with 2 mL of bacteriostatic water, which puts a 1–2 mg dose at about 20 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
Sexual function; use 45 min before